Lisa M. Rimsza

33.9k total citations · 2 hit papers
199 papers, 6.2k citations indexed

About

Lisa M. Rimsza is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Lisa M. Rimsza has authored 199 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Pathology and Forensic Medicine, 86 papers in Oncology and 50 papers in Molecular Biology. Recurrent topics in Lisa M. Rimsza's work include Lymphoma Diagnosis and Treatment (136 papers), Viral-associated cancers and disorders (43 papers) and Chronic Lymphocytic Leukemia Research (35 papers). Lisa M. Rimsza is often cited by papers focused on Lymphoma Diagnosis and Treatment (136 papers), Viral-associated cancers and disorders (43 papers) and Chronic Lymphocytic Leukemia Research (35 papers). Lisa M. Rimsza collaborates with scholars based in United States, Canada and Germany. Lisa M. Rimsza's co-authors include Michael LeBlanc, Richard I. Fisher, Thomas P. Miller, Randy D. Gascoyne, Joseph M. Unger, Daniel O. Persky, Elaine S. Jaffe, Joseph M. Connors, Deborah Fuchs and Denise J. Roe and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Lisa M. Rimsza

186 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of Lenalidomide in Myelodysplastic Syndromes

2005 613 citations Denise J. Roe, Lisa M. Rimsza et al. profile →
ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

2008 583 citations Elaine S. Jaffe, Joseph M. Connors et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lisa M. Rimsza United States	42	3.5k	2.6k	1.6k	1.4k	1.2k	199	6.2k
Yasuhiro Oki United States	40	3.1k 0.9×	2.3k 0.9×	1.7k 1.1×	2.2k 1.6×	1.0k 0.8×	207	6.3k
Sven de Vos United States	41	3.9k 1.1×	3.6k 1.4×	2.6k 1.7×	2.1k 1.5×	1.3k 1.1×	192	7.6k
Lorenz Trümper Germany	42	3.9k 1.1×	3.3k 1.2×	2.1k 1.3×	1.9k 1.4×	1.6k 1.3×	203	7.5k
Michinori Ogura Japan	43	3.2k 0.9×	3.0k 1.1×	1.8k 1.2×	1.2k 0.9×	2.2k 1.8×	223	7.3k
Corrado Tarella Italy	41	2.8k 0.8×	2.8k 1.1×	1.5k 1.0×	1.0k 0.8×	1.3k 1.0×	213	6.2k
Luca Baldini Italy	48	3.7k 1.1×	2.5k 1.0×	2.8k 1.8×	2.3k 1.7×	1.6k 1.3×	261	7.8k
Ivana N. Micallef United States	45	3.3k 0.9×	3.2k 1.2×	1.7k 1.1×	1.3k 1.0×	1.6k 1.3×	256	7.4k
Vincent Ribrag France	46	3.6k 1.0×	4.6k 1.8×	1.7k 1.1×	2.0k 1.4×	1.5k 1.2×	309	7.9k
Kieron Dunleavy United States	36	3.6k 1.0×	2.7k 1.0×	1.6k 1.0×	1.1k 0.8×	827 0.7×	149	5.6k
A. Z. S. Rohatiner United Kingdom	43	4.2k 1.2×	3.1k 1.2×	2.1k 1.4×	854 0.6×	945 0.8×	117	6.8k

Countries citing papers authored by Lisa M. Rimsza

Since Specialization

Citations

This map shows the geographic impact of Lisa M. Rimsza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa M. Rimsza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa M. Rimsza more than expected).

Fields of papers citing papers by Lisa M. Rimsza

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa M. Rimsza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa M. Rimsza. The network helps show where Lisa M. Rimsza may publish in the future.

Co-authorship network of co-authors of Lisa M. Rimsza

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa M. Rimsza. A scholar is included among the top collaborators of Lisa M. Rimsza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa M. Rimsza. Lisa M. Rimsza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Muñoz, Javier, Anagha Deshpande, Lisa M. Rimsza, Grzegorz S. Nowakowski, & Razelle Kurzrock. (2024). Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL. Cancer Treatment Reviews. 124. 102691–102691. 5 indexed citations

Sola‐Visner, Martha, et al.. (2024). Alport syndrome: A puzzling case of thrombocytopenia and giant unusual platelets in blood smear. American Journal of Hematology. 99(6). 1168–1169.

Shadman, Mazyar, Lisa M. Rimsza, John P. Leonard, et al.. (2023). A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016. Hematological Oncology. 41(S2). 116–117. 1 indexed citations

Gibson, Sarah E., Stefan Dojcinov, Snježana Dotlić, et al.. (2023). Mediastinal large B cell lymphoma and surrounding gray areas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 483(6). 733–749. 5 indexed citations

Danilov, Alexey V., Hongli Li, Mazyar Shadman, et al.. (2023). Minimal Residual Disease (MRD) Status Predicts Outcomes in Patients with Follicular Lymphoma (FL) Treated with Chemo-Immunotherapy on SWOG S0016. Blood. 142(Supplement 1). 4359–4359.

Tun, Aung M., Arushi Khurana, Raphael Mwangi, et al.. (2022). Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. Blood Advances. 6(17). 5210–5221. 7 indexed citations

Wisner, Lee, Katie R. Zellner, Betty Glinsmann‐Gibson, et al.. (2021). Assessment of 2-Year Storage Conditions on Protein, RNA, and DNA in Unstained Human Tissue Sections, Including a Novel Multiplex Digital Gene Expression Profiling Method with Implications for Biobanking. Biopreservation and Biobanking. 20(6). 473–484. 3 indexed citations

Frauenfeld, Leonie, Natalia Castrejón de Anta, Joan E. Ramis-Zaldivar, et al.. (2021). Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements. Blood Advances. 6(7). 2361–2372. 33 indexed citations

Demajo, Santiago, Guillem Clot, Giancarlo Castellano, et al.. (2020). A Cyclin D1–Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. Clinical Cancer Research. 27(1). 213–225. 10 indexed citations

10.

Jenjaroenpun, Piroon, Thidathip Wongsurawat, David Tannahill, et al.. (2020). Activation-induced cytidine deaminase localizes to G-quadruplex motifs at mutation hotspots in lymphoma. NAR Cancer. 2(4). zcaa029–zcaa029. 14 indexed citations

11.

Ha, Chul S., Michael LeBlanc, Heiko Schöder, et al.. (2020). Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. Leukemia & lymphoma. 61(10). 2442–2447. 1 indexed citations

12.

Stephens, Deborah M., Hongli Li, Heiko Schöder, et al.. (2019). Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 134(15). 1238–1246. 71 indexed citations

13.

Kamdar, Manali, Hongli Li, Robert W. Chen, et al.. (2019). Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Advances. 3(20). 3132–3135. 15 indexed citations

14.

Kendrick, Samantha, Andrea Murányi, Vijay Gokhale, Laurence H. Hurley, & Lisa M. Rimsza. (2017). Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth. Journal of Medicinal Chemistry. 60(15). 6587–6597. 35 indexed citations

15.

Rimsza, Lisa M., Stefania Pittaluga, Stephan Dirnhofer, et al.. (2017). The clinicopathologic spectrum of mature aggressive B cell lymphomas. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 471(4). 453–466. 17 indexed citations

16.

Press, Oliver W., Joseph M. Unger, Lisa M. Rimsza, et al.. (2013). A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab. Clinical Cancer Research. 19(23). 6624–6632. 32 indexed citations

17.

Press, Oliver W., Joseph M. Unger, Lisa M. Rimsza, et al.. (2012). Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus ¹³¹ Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016. Journal of Clinical Oncology. 31(3). 314–320. 123 indexed citations

18.

Qi, Wenqing, Laurence Cooke, Xiaobing Liu, et al.. (2011). Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochemical Pharmacology. 81(7). 881–890. 76 indexed citations

19.

Rimsza, Lisa M., Michael LeBlanc, Joseph M. Unger, et al.. (2008). Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood. 112(8). 3425–3433. 108 indexed citations

20.

Sola, Martha C., et al.. (2004). A Neonate with Severe Thrombocytopenia and Radio-Ulnar Synostosis. Journal of Perinatology. 24(8). 528–530. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact